Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab
M200, Carboplatin, Paclitaxel, Bevacizumab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Escalating doses of volociximab at 10, 20, and 30 mg/kg with carboplatin, paclitaxel, and bevacizumab |
| Name | Type | Description |
|---|---|---|
| M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab | DRUG | Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin. |
Inclusion Criteria * Males and females of at least 18 years of age. * Stage IIIB with pleural effusion or Stage IV non-squamous NSCLC. * Measurable and/or evaluable disease according to RECIST. * No prior chemotherapy, biological therapy or immunotherapy for Stage IIIB/IV disease. Adjuvant therapy ...
Top 20 of 79 competitors
M200 is an investigational monoclonal antibody that was studied in combination with carboplatin, paclitaxel, and bevacizumab as a first-line treatment for advanced non-small cell lung cancer (NSCLC). It was evaluated in a single Phase 1b trial and is not an approved therapy.
M200, also known as volociximab, is a monoclonal antibody that targets integrin alpha-5 beta-1. This integrin is involved in cell adhesion and migration. By binding to it, M200 was designed to interfere with processes that support tumor growth and survival.
M200 was developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker ABT. The company sponsored the Phase 1b study of M200 in combination with carboplatin, paclitaxel, and bevacizumab for advanced non-small cell lung cancer.
M200 is in Phase 1 development. It has been evaluated in one completed Phase 1b clinical trial. The drug is investigational and has not been approved by the FDA for any indication.
M200 was studied in a single Phase 1b trial, NCT00666692, titled a study of volociximab in combination with carboplatin, paclitaxel, and bevacizumab in first-line advanced non-small cell lung cancer. The trial was completed and enrolled 7 participants in the United States.
Yes, M200 is also known as volociximab. The two names refer to the same monoclonal antibody. Volociximab is the international nonproprietary name, while M200 is the development code used by Abbott Laboratories.